Advertisement

Document › Details
BioNTech SE. (12/28/22). "Press Release: BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference". Mainz.
![]() |
Region | San Francisco, CA |
Country | United States (USA) | |
![]() |
Organisation | BioNTech SE (Nasdaq: BNTX) |
Group | BioNTech (Group) | |
Organisation 2 | J.P. Morgan Securities LLC | |
Group | JPMorgan Chase (Group) | |
![]() |
Product | J.P. Morgan 41st Annual Healthcare Conference 2023 San Francisco |
Product 2 | mRNA-based vaccine | |
![]() |
Index term | BioNTech–JPMorgan Chase: investor conference, 202301 supply service BioNTech presents at JP Morgan Healthcare Conference 2023 |
![]() |
Person | Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH) |
Person 2 | Maas, Sylke (BioNTech 202005 VP Investor Relations + Business Strategy) | |
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Prof. Ugur Sahin, M.D., will present a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PST / 12:45 pm ET.
A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.com/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit www.BioNTech.com.
CONTACT
Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
[email protected]
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
[email protected]
Record changed: 2024-01-06 |
Advertisement

More documents for BioNTech (Group)
- [1] BioNTech SE. (11/13/24). "Press Release: BioNTech to Acquire Biotheus to Boost Oncology Strategy". Mainz....
- [2] Tempus AI, Inc.. (9/4/24). "Press Release: Tempus Announces Real World Data Collaboration with BioNTech". Chicago....
- [3] BioNTech SE. (8/22/24). "Press Release: Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine". New York, NY & Mainz....
- [4] BioNTech SE. (8/19/24). "Press Release: Lift of Partial Clinical Hold for BNT326/YL202"....
- [5] BioNTech SE. (8/16/24). "Press Release: Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age". New York, NY & Mainz....
- [6] BioNTech SE. (8/5/24). "Press Release: BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update". Mainz....
- [7] Triastek, Inc.. (7/23/24). "Press Release: Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech to Advance 3D Printed Oral RNA Therapeutics". Nanjing....
- [8] Haya Therapeutics SA. (7/1/24). "Press Release: Haya Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award". Lausanne & San Diego, CA....
- [9] BioNTech SE. (6/24/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer". Mainz & Shanghai....
- [10] BioNTech SE. (5/29/24). "Press Release: BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem". Mainz & Oslo....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top